RUTHERFORD, N.J., Aug. 3, 2015 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), an emerging leader in DNA-based cancer diagnostics, announced today the first scientific presentation of the application of its proprietary B-cell lymphoma NGS panel entitled, "Clinico- and Pathogenomic Analysis of A Single Institution Diffuse Large B-cell Lymphoma (DLBCL) Cohort." The presentation will take place on Monday, August 3rd at 10:15am (Mountain Time) at the Cancer Genomics Consortium and the Cytogenomics Array Group Meeting (CGC-CAGdb) in Denver, Colorado. The unique next-generation sequencing (NGS) panel is an extension of CGI's extensive discovery and diagnostic development in hematologic cancers.
CGI's new NGS panel is disease-focused and designed to detect variants in 220 genes, including 163 enriched for Diffuse Large B-cell Lymphoma (DLBCL), 140 for Follicular Lymphoma (FL), and 55 for Mantle Cell Lymphoma (MCL). The test also includes an extension of CGI's NGS panel for Chronic Lymphocytic Leukemia (CLL), Focus::CLL™, already offered in its CLIA certified laboratory. The Focus:CLL panel is currently being used in multiple clinical trials and is in routine clinical use to provide prognostic information for patient management. In addition to the seven clinically relevant genes already profiled by the CLL panel, the addition of the frequently mutated genes XPO1, MED12, POT1, and CDKN2A, as well as PLCG2 and BTK with emerging roles in resistance to current targeted therapies in CLL will enable physicians to better guide patient treatment and management.
Half of the genes profiled in the new NGS-based B-Cell focused Lymphoma panel are not currently profiled in other commercially available, large-scale NGS panels. The customized and disease-focused approach CGI has undertaken to profile these specific B-cell malignancies will give the lymphoma panel a competitive edge in the marketplace by providing more clinically relevant and actionable information in an efficient NGS panel.
The test, which is optimized for sequencing of formalin-fixed paraffin-embedded (FFPE) tissue, is expected to launch in the fourth quarter of 2015.
About Cancer Genetics
Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics. Our tests target difficult to diagnose hematological, urogenital and HPV-associated cancers. They are designed to guide the prognosis and treatment of these cancers with the goal of improving outcomes for patients. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.
We also offer a comprehensive range of oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals and biopharmaceutical companies. Our state-of-the-art reference labs are CLIA certified and CAP accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow us:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that the transaction will not close or, if it closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended March 31, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.